Skip to content
← Full study record

NCT02064387 · OUTCOME

Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916 · Source last updated 2020-08-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
Picograms per milliliter
Interval / dispersion
Geometric Coefficient of Variation
Time frame
Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1), Pre-dose and EOI of Day 1 (Cycle 2 and Cycle 4)

What was measured

Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.

Analysis population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Groups in this outcome

Part 1: GSK2857916 0.03 mg/kg

Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).

Part 1: GSK2857916 0.06 mg/kg

Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).

Part 1: GSK2857916 0.12 mg/kg

Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).

Part 1: GSK2857916 0.24 mg/kg

Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).

Part 1: GSK2857916 0.48 mg/kg

Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).

Part 1: GSK2857916 0.96 mg/kg

Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).

Part 1: GSK2857916 1.92 mg/kg

Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).

Part 1: GSK2857916 3.40 mg/kg

Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).

Part 1: GSK2857916 4.60 mg/kg

Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 1: GSK2857916 0.03 mg/kg1
Part 1: GSK2857916 0.06 mg/kg1
Part 1: GSK2857916 0.12 mg/kg4
Part 1: GSK2857916 0.24 mg/kg4
Part 1: GSK2857916 0.48 mg/kg4
Part 1: GSK2857916 0.96 mg/kg3
Part 1: GSK2857916 1.92 mg/kg4
Part 1: GSK2857916 3.40 mg/kg3
Part 1: GSK2857916 4.60 mg/kg6

Reported measurements

Day 1, Cycle 1,n=0,1,4,2,1,3,3,2,6

Analysis denominator · Participants

GroupSource count
Part 1: GSK2857916 0.03 mg/kg0
Part 1: GSK2857916 0.06 mg/kg1
Part 1: GSK2857916 0.12 mg/kg4
Part 1: GSK2857916 0.24 mg/kg2
Part 1: GSK2857916 0.48 mg/kg1
Part 1: GSK2857916 0.96 mg/kg3
Part 1: GSK2857916 1.92 mg/kg3
Part 1: GSK2857916 3.40 mg/kg2
Part 1: GSK2857916 4.60 mg/kg6
Values in Picograms per milliliter · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Part 1: GSK2857916 0.06 mg/kgNANANot reportedNot reportedNA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Part 1: GSK2857916 0.12 mg/kgNANANot reportedNot reportedNA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Part 1: GSK2857916 0.24 mg/kgNANANot reportedNot reportedNA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Part 1: GSK2857916 0.48 mg/kgNANANot reportedNot reportedNA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Part 1: GSK2857916 0.96 mg/kgNANANot reportedNot reportedNA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Part 1: GSK2857916 1.92 mg/kgNANANot reportedNot reportedNA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Part 1: GSK2857916 3.40 mg/kgNANANot reportedNot reportedNA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Part 1: GSK2857916 4.60 mg/kgNANANot reportedNot reportedNA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Day 1, Cycle 2,n=0,1,0,2,1,2,2,2,5

Analysis denominator · Participants

GroupSource count
Part 1: GSK2857916 0.03 mg/kg0
Part 1: GSK2857916 0.06 mg/kg1
Part 1: GSK2857916 0.12 mg/kg0
Part 1: GSK2857916 0.24 mg/kg2
Part 1: GSK2857916 0.48 mg/kg1
Part 1: GSK2857916 0.96 mg/kg2
Part 1: GSK2857916 1.92 mg/kg2
Part 1: GSK2857916 3.40 mg/kg2
Part 1: GSK2857916 4.60 mg/kg5
Values in Picograms per milliliter · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Part 1: GSK2857916 0.06 mg/kgNANANot reportedNot reportedNA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Part 1: GSK2857916 0.24 mg/kgNANANot reportedNot reportedNA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Part 1: GSK2857916 0.48 mg/kgNANANot reportedNot reportedNA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Part 1: GSK2857916 0.96 mg/kgNANANot reportedNot reportedNA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Part 1: GSK2857916 1.92 mg/kgNANANot reportedNot reportedNA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Part 1: GSK2857916 3.40 mg/kgNANANot reportedNot reportedNA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Part 1: GSK2857916 4.60 mg/kgNANANot reportedNot reportedNA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Day 1, Cycle 4,n=0,0,0,0,0,0,0,0,0

Analysis denominator · Participants

GroupSource count
Part 1: GSK2857916 0.03 mg/kg0
Part 1: GSK2857916 0.06 mg/kg0
Part 1: GSK2857916 0.12 mg/kg0
Part 1: GSK2857916 0.24 mg/kg0
Part 1: GSK2857916 0.48 mg/kg0
Part 1: GSK2857916 0.96 mg/kg0
Part 1: GSK2857916 1.92 mg/kg0
Part 1: GSK2857916 3.40 mg/kg0
Part 1: GSK2857916 4.60 mg/kg0
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
        group Id
        OG001
        spread
        NA
        value
        NA
      2. comment
        NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
        group Id
        OG002
        spread
        NA
        value
        NA
      3. comment
        NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
        group Id
        OG003
        spread
        NA
        value
        NA
      4. comment
        NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
        group Id
        OG004
        spread
        NA
        value
        NA
      5. comment
        NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
        group Id
        OG005
        spread
        NA
        value
        NA
      6. comment
        NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
        group Id
        OG006
        spread
        NA
        value
        NA
      7. comment
        NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
        group Id
        OG007
        spread
        NA
        value
        NA
      8. comment
        NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
        group Id
        OG008
        spread
        NA
        value
        NA
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
      3. group Id
        OG002
        value
        4
      4. group Id
        OG003
        value
        2
      5. group Id
        OG004
        value
        1
      6. group Id
        OG005
        value
        3
      7. group Id
        OG006
        value
        3
      8. group Id
        OG007
        value
        2
      9. group Id
        OG008
        value
        6
      units
      Participants
    title
    Day 1, Cycle 1,n=0,1,4,2,1,3,3,2,6
  2. categories
    1. measurements
      1. comment
        NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
        group Id
        OG001
        spread
        NA
        value
        NA
      2. comment
        NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
        group Id
        OG003
        spread
        NA
        value
        NA
      3. comment
        NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
        group Id
        OG004
        spread
        NA
        value
        NA
      4. comment
        NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
        group Id
        OG005
        spread
        NA
        value
        NA
      5. comment
        NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
        group Id
        OG006
        spread
        NA
        value
        NA
      6. comment
        NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
        group Id
        OG007
        spread
        NA
        value
        NA
      7. comment
        NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
        group Id
        OG008
        spread
        NA
        value
        NA
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        2
      5. group Id
        OG004
        value
        1
      6. group Id
        OG005
        value
        2
      7. group Id
        OG006
        value
        2
      8. group Id
        OG007
        value
        2
      9. group Id
        OG008
        value
        5
      units
      Participants
    title
    Day 1, Cycle 2,n=0,1,0,2,1,2,2,2,5
  3. denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        0
      6. group Id
        OG005
        value
        0
      7. group Id
        OG006
        value
        0
      8. group Id
        OG007
        value
        0
      9. group Id
        OG008
        value
        0
      units
      Participants
    title
    Day 1, Cycle 4,n=0,0,0,0,0,0,0,0,0
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    2. group Id
      OG001
      value
      1
    3. group Id
      OG002
      value
      4
    4. group Id
      OG003
      value
      4
    5. group Id
      OG004
      value
      4
    6. group Id
      OG005
      value
      3
    7. group Id
      OG006
      value
      4
    8. group Id
      OG007
      value
      3
    9. group Id
      OG008
      value
      6
    units
    Participants
description
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
    id
    OG000
    title
    Part 1: GSK2857916 0.03 mg/kg
  2. description
    Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
    id
    OG001
    title
    Part 1: GSK2857916 0.06 mg/kg
  3. description
    Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
    id
    OG002
    title
    Part 1: GSK2857916 0.12 mg/kg
  4. description
    Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
    id
    OG003
    title
    Part 1: GSK2857916 0.24 mg/kg
  5. description
    Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
    id
    OG004
    title
    Part 1: GSK2857916 0.48 mg/kg
  6. description
    Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
    id
    OG005
    title
    Part 1: GSK2857916 0.96 mg/kg
  7. description
    Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
    id
    OG006
    title
    Part 1: GSK2857916 1.92 mg/kg
  8. description
    Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
    id
    OG007
    title
    Part 1: GSK2857916 3.40 mg/kg
  9. description
    Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
    id
    OG008
    title
    Part 1: GSK2857916 4.60 mg/kg
param Type
GEOMETRIC_MEAN
population Description
PK Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
reporting Status
POSTED
time Frame
Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1), Pre-dose and EOI of Day 1 (Cycle 2 and Cycle 4)
title
Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1
type
SECONDARY
unit Of Measure
Picograms per milliliter

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice